Cancer Awareness

बिहार: गांधी मैदान में मंत्रिमंडल के सदस्य लेंगे शपथ शपथ ग्रहण समारोह को देखते हुए आम लोगों के लिए गांधी मैदान किया गया बंद शपथ ग्रहण समारोह के लिए गांधी मैदान में लगाया जा रहा है हैंगर शपथ ग्रहण समारोह में प्रधानमंत्री नरेंद्र मोदी भी हो सकते हैं शामिल 6 मई के बाद कभी भी हो सकता है शपथ ग्रहण समारोह मई महीने के पहले ही सप्ताह में होगा शपथ ग्रहण पीएम मोदी के साथ देश भर के कई बड़े नेता शपथ ग्रहण समारोह में होंगे शामिल.

🚨 FSSAI Proposes Ban on Plastic Sachets in Pan Masala, Gutkha Packaging

Meet the Next Big Campaign. In the coming days, we will start exposing the corruption hidden behind the “Smart Cities Mission.” Thousands of crores were allocated to cities across India in the name of “Smart Development.” But in many places, that money seems to have vanished into the pockets of corrupt officials and babus, while citizens were handed useless showpieces like selfie points, cosmetic beautification, and hollow PR. Smart City for them. Smart loot for the system. Nothing smart for the public. Just wait and watch. 🙏

Over 50,000 people in the U.S. die from pancreatic cancer every year. After this drug is approved and widely used, that number will remain essentially the same. In absolute terms, they are reporting a median survival shift of around six months. Yet we know resistance inevitably develops, as it does in all cancers subjected to drugs targeting mutations in the RAS/MAPK/PI3K pathway. If the goal is to meaningfully reduce cancer mortality, this does not move the needle. This is where decades of focus and billions in NIH/NCI funding have concentrated. National Cancer Institute is funded at roughly $9 billion per year, and a substantial portion of that budget is devoted to oncogenes and what is marketed as targeted therapies. This is then layered on top of a drug development and healthcare model where drugs like this can cost over $100,000 per patient. These are incremental gains at the late metastatic stage, where the biology is already stacked against you. Meanwhile, the two areas that actually determine population-level outcomes—early detection and prevention—remain neglected. If we are serious about reducing the number of people who die from pancreatic cancer, the priority cannot be continuing to optimize late-stage interventions that predictably yield temporary gains. The goal should be zero deaths. Right now, we are not on a path that gets us there. It is not surprising that this view is being met with backlash. Much of the criticism is coming from people whose incentives—academic , financial, or institutional—are tied to maintaining the current system in biomedical research and the biotech and pharma sectors that profit from it.